Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients with Lymphoma
- León, N.G. 16
- Delgado-Bolton, R.C. 23812
- Del Campo Del Val, L. 6
- Cabezas, B. 5
- Arranz, R. 6
- García, M. 5
- Cannata, J. 5
- González Ortega, S. 6
- Pérez Sáez, A.M. 4
- López-Botet, B. 9
- Rodríguez-Vigil, B. 10
- Mateo, M. 5
- Colletti, P.M. 11
- Rubello, D. 7
- Carreras, J.L. 8
-
1
Universidad Autónoma de Madrid
info
-
2
Centro de Investigación Biomédica de La Rioja
info
-
3
Universidad de La Rioja
info
- 4 Department of Haematology, United Kingdom
-
5
Hospital Clínico San Carlos de Madrid
info
-
6
Hospital Universitario de la Princesa
info
- 7 Department of Nuclear Medicine, Imaging and Clinical Pathology, Santa Maria della Misericordia Hospital, Rovigo, Italy
-
8
Nuclear Institute for Agriculture and Biology
info
-
9
Fundación Jiménez Díaz
info
-
10
Hospital Txagorritxu
info
-
11
University of Southern California
info
-
12
Hospital San Pedro
info
ISSN: 0363-9762
Datum der Publikation: 2017
Ausgabe: 42
Nummer: 8
Seiten: 595-602
Art: Artikel
Andere Publikationen in: Clinical Nuclear Medicine
Indikatoren
Zitate erhalten
JCR (Journal Impact Factor)
- Jahr 2017
- Impact Factor der Zeitschrift: 6.309
- Impact Factor ohne Selbstzitierung: 4.126
- Article influence score: 0.882
- Höchstes Quartil: Q1
- Bereich: RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Quartil: Q1 Position im Bereich: 6/129 (Ausgabe: SCIE)
SCImago Journal Rank
- Jahr 2017
- Impact SJR der Zeitschrift: 0.652
- Höchstes Quartil: Q2
- Bereich: Medicine (miscellaneous) Quartil: Q2 Position im Bereich: 1051/2937
- Bereich: Radiology, Nuclear Medicine and Imaging Quartil: Q2 Position im Bereich: 114/358
Scopus CiteScore
- Jahr 2017
- CiteScore der Zeitschrift: 2.3
- Bereich: Radiology, Nuclear Medicine and Imaging Perzentil: 48
Journal Citation Indicator (JCI)
- Jahr 2017
- JCI der Zeitschrift: 0.98
- Höchstes Quartil: Q1
- Bereich: RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Quartil: Q1 Position im Bereich: 35/181
Zusammenfassung
Objectives To compare staging correctness between contrast-enhanced FDG PET/ceCT and 64-slice multi-detector-row CT (ceCT64) for initial staging and response evaluation at the end of treatment (EOT) in patients with Hodgkin lymphoma, diffuse large B cell lymphoma (DLBCL), and follicular lymphoma. Methods This prospective study compared initial staging and response evaluation at EOT. One hundred eighty-one patients were randomly assigned to either ceCT64 or FDG PET/ceCT. A nuclear medicine physician and a radiologist read FDG PET/ceCT scans independently and achieved post hoc consensus, whereas another independent radiologist interpreted ceCT64 separately. The reference standard included all clinical information, all tests, and follow-up. Ethics committees of the participating centers approved the study, and all participants provided written consent. Results Ninety-one patients were randomized to ceCT64 and 90 to FDG PET/ceCT; 72 had Hodgkin lymphoma, 72 had DLBCL, and 37 had follicular lymphoma. There was excellent correlation between the reference standard and initial staging for both FDG PET/ceCT (κ = 0.96) and ceCT64 (κ = 0.84), although evaluation of the response at EOT was excellent only for FDG PET/ceCT (κ = 0.91). Conclusions Our study demonstrated satisfactory agreement between FDG PET/ceCT (κ = 0.96) and ceCT64 (κ = 0.84) in initial staging compared with the reference standard (P = 0.16). Response evaluation at EOT with FDG PET/ceCT (κ = 0.91) was superior compared with ceCT64 (κ = 0.307) (P < 0.001). © 2017 Wolters Kluwer Health, Inc. All rights reserved.